相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival
Najla Itani et al.
CLINICAL BREAST CANCER (2020)
Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence
Jingjing Zhu et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Identification of 6′-β-fluoro-homoaristeromycin as a potent inhibitor of chikungunya virus replication
Young Sup Shin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Antitumor Activity of Ohmyungsamycin A through the Regulation of the Skp2-p27 Axis and MCM4 in Human Colorectal Cancer Cells
Woong Sub Byun et al.
JOURNAL OF NATURAL PRODUCTS (2020)
Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression
Thomas J. Rogers et al.
MOLECULAR CANCER RESEARCH (2019)
c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL
Ho Yeon Lee et al.
MOLECULAR CANCER RESEARCH (2019)
Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells
Giovanni Nassa et al.
SCIENCE ADVANCES (2019)
Nucleoside Analogues as Antibacterial Agents
Jessica M. Thomson et al.
FRONTIERS IN MICROBIOLOGY (2019)
Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia
Aditya Barve et al.
CELLS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer
Woong Sub Byun et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Esculetin suppresses tumor growth and metastasis by targeting Axin2/E-cadherin axis in colorectal cancer
Won Kyung Kim et al.
BIOCHEMICAL PHARMACOLOGY (2018)
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein et al.
BLOOD (2018)
Design, synthesis and anticancer activity of fluorocyclopentenyl-purines and - pyrimidines
Ji-seong Yoon et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Depsidomycins B and C: New Cyclic Peptides from a Ginseng Farm Soil-Derived Actinomycete
Yun Kwon et al.
MOLECULES (2018)
Innovations and Challenges in the Treatment of Metastatic Triple-Negative Breast Cancer
Heather L. McArthur
JOURNAL OF ONCOLOGY PRACTICE (2018)
Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
Nikolaos Tsesmetzis et al.
CANCERS (2018)
A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer
Woong Sub Byun et al.
BIOCHEMICAL PHARMACOLOGY (2018)
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Ji Hyun Park et al.
ESMO OPEN (2018)
Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development
C. T. Tsai et al.
ONCOGENE (2017)
Epigenetics in cancer stem cells
Tan Boon Toh et al.
MOLECULAR CANCER (2017)
Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time
Jennifer C. Melvin et al.
BRITISH JOURNAL OF CANCER (2016)
Histone lysine methyltransferases as anti-cancer targets for drug discovery
Qing Liu et al.
ACTA PHARMACOLOGICA SINICA (2016)
Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma
Lilly Y. W. Bourguignon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
Marco Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome
Min Hye Jang et al.
HUMAN PATHOLOGY (2015)
Structure-Activity Relationships of Neplanocin A Analogues as S-Adenosylhomocysteine Hydrolase Inhibitors and Their Antiviral and Antitumor Activities
Girish Chandra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression
Min-Hyung Cho et al.
NATURE COMMUNICATIONS (2015)
DOT1L: a new therapeutic target for aggressive breast cancer
Jeong-Yeon Lee et al.
ONCOTARGET (2015)
Factors associated with breast cancer mortality after local recurrence
R. Dent et al.
CURRENT ONCOLOGY (2014)
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents
Magdalena Klanova et al.
MOLECULAR CANCER (2014)
Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer
Li Zhang et al.
ONCOTARGET (2014)
Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
C. Zagni et al.
CURRENT MEDICINAL CHEMISTRY (2013)
G9a, a multipotent regulator of gene expression
Shilpa Rani Shankar et al.
EPIGENETICS (2013)
Adenosine receptors as drug targets - what are the challenges?
Jiang-Fan Chen et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Lars Petter Jordheim et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Wenyu Yu et al.
NATURE COMMUNICATIONS (2012)
The diverse functions of Dot1 and H3K79 methylation
Anh Tram Nguyen et al.
GENES & DEVELOPMENT (2011)
Selective Inhibitors of Histone Methyltransferase DOT1L: Design, Synthesis, and Crystallographic Studies
Yuan Yao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Adenosine receptors as therapeutic targets
KA Jacobson et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai et al.
NATURE PROTOCOLS (2006)
Synthesis of fluorinated cyclopentenyladenine as potent inhibitor of S-adenosylhomocysteine hydrolase
HO Kim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy
VL Damaraju et al.
ONCOGENE (2003)
Design, synthesis, and biological evaluation of fluoroneplanocin A as the novel mechanism-based inhibitor of S-adenosylhomocysteine hydrolase
LS Jeong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Synthesis and biological evaluation of halo-neplanocin A as novel mechanism-based inhibitors of S-Adenosylhomocysteine hydrolase
LS Jeong et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2003)
Stereoselective synthesis of a novel apio analogue of neplanocin A as potential S-adenosylhomocysteine hydrolase inhibitor
HR Moon et al.
ORGANIC LETTERS (2002)
A histone H3 methyltransferase controls DNA methylation in Neurospora crassa
H Tamaru et al.
NATURE (2001)
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
CM Galmarini et al.
LEUKEMIA (2001)
分享论文
